Ruth Schneider
Overview
Explore the profile of Ruth Schneider including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
648
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee H, Kadaru T, Schneider R, Triana T, Tujardon C, Ayers C, et al.
Am J Prev Cardiol
. 2025 Feb;
21:100937.
PMID: 40007938
Objective: Familial Hypercholesterolemia (FH) is underdiagnosed and undertreated. Several electronic health record (EHR) algorithms have been developed to improve identification of patients with FH. The approach to improving downstream processes...
2.
Kogel A, Ladopoulos T, Schwake C, Kleiter I, Teegen B, Siems N, et al.
Neurol Neuroimmunol Neuroinflamm
. 2024 Oct;
11(6):e200325.
PMID: 39393044
Background And Objectives: Cognitive impairment is a common and challenging symptom in multiple sclerosis and neuromyelitis optica spectrum disease; however, data in myelin oligodendrocyte glycoprotein-IgG-associated disease (MOGAD) remain scarce. In...
3.
Schneider R, Kogel A, Ladopoulos T, Siems N, Krieger B, Bellenberg B, et al.
Ann Clin Transl Neurol
. 2024 Jul;
11(8):2166-2175.
PMID: 39054631
Objectives: Global brain volume changes in patients with myelin oligodendrocyte glycoprotein antibody-associated disease compared with healthy controls (HC) could be revealed by magnetic resonance imaging, but specific atrophy patterns of...
4.
Cortese R, Battaglini M, Prados F, Gentile G, Luchetti L, Bianchi A, et al.
Ann Neurol
. 2024 May;
96(2):276-288.
PMID: 38780377
Objective: To evaluate: (1) the distribution of gray matter (GM) atrophy in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4+NMOSD), and relapsing-remitting multiple sclerosis (RRMS);...
5.
Kreimer F, Aweimer A, El-Battrawy I, Labedi A, Schneider R, Haghikia A, et al.
Neurol Sci
. 2024 Apr;
45(10):4903-4912.
PMID: 38664303
Background: In patients with embolic stroke of undetermined source (ESUS), underlying subclinical atrial fibrillation (AF) is often suspected. Previous studies identifying predictors of AF have been limited in their ability...
6.
Yazici I, Krieger B, Bellenberg B, Ladopoulos T, Gold R, Schneider R, et al.
Neuroradiology
. 2023 Dec;
66(2):193-205.
PMID: 38110539
Purpose: We aimed to validate the estimation of the brain parenchymal fraction (BPF) in patients with multiple sclerosis (MS) using synthetic magnetic resonance imaging (SyMRI) by comparison with software tools...
7.
Salmen A, Hoepner R, Fleischer V, Heldt M, Gisevius B, Motte J, et al.
Ther Adv Neurol Disord
. 2023 Sep;
16:17562864231197309.
PMID: 37692259
Background: Depression has a major impact on the disease burden of multiple sclerosis (MS). Analyses of overlapping MS and depression risk factors [smoking, vitamin D (25-OH-VD) and Epstein-Barr virus (EBV)...
8.
Gomes A, Kulsvehagen L, Lipps P, Cagol A, Cerda-Fuertes N, Neziraj T, et al.
JAMA Neurol
. 2023 Aug;
80(9):989-995.
PMID: 37548987
Importance: Differential diagnosis of patients with seronegative demyelinating central nervous system (CNS) disease is challenging. In this regard, evidence suggests that immunoglobulin (Ig) A plays a role in the pathogenesis...
9.
Cortese R, Battaglini M, Prados F, Bianchi A, Haider L, Jacob A, et al.
Brain
. 2022 Dec;
146(6):2489-2501.
PMID: 36515653
MRI and clinical features of myelin oligodendrocyte glycoprotein (MOG)-antibody disease may overlap with those of other inflammatory demyelinating conditions posing diagnostic challenges, especially in non-acute phases and when serologic testing...
10.
Matusche B, Litvin L, Schneider R, Bellenberg B, Muhlau M, Pongratz V, et al.
Eur J Neurol
. 2022 Nov;
30(2):453-462.
PMID: 36318271
Background And Purpose: Brain pseudoatrophy has been shown to play a pivotal role in the interpretation of brain atrophy measures during the first year of disease-modifying therapy in multiple sclerosis....